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Objectives : The purposes of this study is to estimate the
cost of cancer care after its diagnosis and to identify factors
that can influence the cost of cancer care.
Methods : The study subjects were patients with an initial
diagnosis one of four selected tumors and had their first
two-years of cancer care at a national cancer center. The
data were obtained from medical records and patient
surveys. We classified cancer care costs into medical and
nonmedical costs, and each cost was analyzed for burden
type, medical service, and cancer stage according to
cancer types. Factors affecting cancer care costs for the
initial phase included demographic variables, socioeco-
nomic status and clinical variables. 
Results : Cancer care costs for the initial year following
diagnosis were higher than the costs for the following
successive year after diagnosis. Lung cancer (25,648,000
won) had higher costs than the other three cancer types. Of
the total costs, patent burden was more than 50% and
medical costs accounted for more than 60%. Inpatient costs
accounted for more than 60% of the medical costs for
stomach and liver cancer in the initial phase. Care for late-
stage cancer was more expensive than care for early-stage
cancer. Nonmedical costs were estimated to be between
4,500,000 to 6,000,000 won wi th expenses for  the
caregiver being the highest. The factors affecting cancer
care costs were treatment type and cancer stage.
Conclusions : The cancer care costs after diagnosis are
substantial and vary by cancer site, cancer stage and
treatment type.  I t  is  usefu l  for  pol icy makers and
researchers to ident i fy  tumor-speci f ic  medical  and
nonmedical costs. The effort to reduce cancer costs and
early detection for cancer can reduce the burden to society
and improve quality of life for the cancer patients.
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Table 1. Characteristics of study subjects
Characteristics
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NHI: National Health Insurance, CRx: chemotherapy including hormone therapy, TACE: transarterial chemoembolization, RFA: radiofrequency ablation, PEIT: percutaneous ethanol injection
therapy, RT: radiotherapy
* Procedure: in case of colorectal cancer, stomach cancer, liver cancer, breast cancer, Procedure: in case of lung cancer, Cancer stage: in case of colorectal cancer, stomach cancer, liver
cancer, breast cancer, non-small cell lung cancer, Cancer stage: in case of small cell lung cancer, In case of performing treatment
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Table 2. Costs by type of burden and medical service                                                                                                                                   (Unit: Thousand Won, per capita)
Cancer site Phase of care Type of burden
Medical costs









































































































































































































































































































































































































































CAM: complementary and alterative medicine
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Figure 1. Proportion of medical costs by medical services.
Table 3. Costs by stage at diagnosis and cancer site                                       (Unit: Thousand Won, per capita)
Cancer site Stage
Initial phase
no. Medical costs Non-medical
costs
Continuing phase























































































































































































Table 4. Factors affecting initial costs of cancer care
Variables
Stomach







































NHI: National Health Insurance, CRx: chemotherapy including hormone therapy, TACE: transarterial chemoembolization,
RFA: radiofrequency ablation, PEIT: percutaneous ethanol injection therapy, RT: radiotherapy
*  Procedure: in case of colorectal cancer, stomach cancer, liver cancer, breast cancer, Procedure: in case of lung cancer,
Cancer stage: in case of colorectal cancer, stomach cancer, liver cancer, breast cancer, Cancer stage: in case of lung
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